Preparation of virus-free pyridoxylated hemoglobin from the blood of HBV or HTLV-I healthy carriers.

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Preparation of virus-free pyridoxylated hemoglobin from the blood of HBV or HTLV-I healthy carriers.

Biomater Artif Cells Artif Organs. 1988;16(1-3):113-21. Unique Identifier : AIDSLINE MED/89027148
Sekiguchi S; Ito K; Kobayashi M; Ototake N; Kosuda M; Kwon KW; Ikeda H; Research Division, Hokkaido Red Cross Blood Center, Sapporo,; Japan.

Abstract: One of our major aims was to find ways to utilize outdated or virus-contaminated blood. Pyridoxylated hemoglobin (PLP-Hb), a possible substitute for red cells as an artificial oxygen carrier was prepared from outdated human blood. By conjugation with polyethylene glycol (PEG), the biological half life was increased about 3 folds at 82% blood replacement in rats without significant side effects in vivo or in vitro. We next tried to prepare virus-free PEG-PLP-Hb from HBV or HTLV-I positive blood. A considerable amount of HBV (Dane particles) could be removed from HBV-positive red cells by washing and during the preparation of PEG-PLP-Hb. When the hemoglobin preparations containing Dane particles were filtered through a porous cellulose filter, BMM-30 (30 nm pore size, Asahi Chemical Industry Co., Ltd., Osaka, Japan), HBV-DNA in the filtered fractions became less than 0.33% of the initial amount. More than 96% of blood leukocytes could be removed with a leukocyte removal filter, Sepacell R-500 (Asahi Medical Co., Ltd., Tokyo, Japan). The leukocytes collected from filtrated fractions of HTLV-I positive blood did not survive beyond 3 days. Since transmission of HTLV-I occurs by cell to cell contact and is rare in cell-Free condition, it is unlikely that the PLP-Hb prepared from HTLV-I positive blood which is deprived of leukocytes transmits HTLV-I infection.

Keywords: Animal Blood/*MICROBIOLOGY Blood Component Removal/*METHODS *Blood Substitutes Cell Separation Centrifugation, Density Gradient Chemistry Chemistry, Physical DNA, Viral/ANALYSIS Erythrocytes/CYTOLOGY Exchange Transfusion, Whole Blood Filtration Half-Life Hemoglobins/*ISOLATION & PURIF/PHARMACOKINETICS Hepatitis B Surface Antigens/ANALYSIS Hepatitis B Virus/GENETICS/*ISOLATION & PURIF Human HIV/*ISOLATION & PURIF Leukocytes/CYTOLOGY Male Polyethylene Glycols/PHARMACOKINETICS Pyridoxal Phosphate/ANALOGS & DERIVATIVES Rats JOURNAL ARTICLE

890228
M8920496

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .